Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

About this trial

The PANENCA trial aims to reduce postoperative complications in patients undergoing pancreatoduodenectomy (also known as a Whipple procedure), a complex surgical operation performed to remove tumors located in or near the head of the pancreas. One of the most frequent and serious complications after this surgery is postoperative pancreatic fistula (POPF), a leakage of pancreatic fluid from the surgical connection. POPF can lead to intra-abdominal infection, bleeding, and inflammation, often resulting in delayed recovery and postponement of subsequent oncological treatment. In severe cases, these complications may be life-threatening.

Patients with a small main pancreatic duct (3 millimeters or less) are known to have a substantially higher risk of developing POPF. Previous studies have shown that several existing interventions may reduce the risk or severity of these complications. These include hydrocortisone, a medication that suppresses postoperative inflammation; octreotide, a medication that reduces the production of pancreatic secretions; and a surgical technique known as the ligamentum teres hepatis patch, which uses the patient's own tissue to protect nearby blood vessels in the event of a pancreatic leak.

Because the development of pancreatic fistulas is multifactorial, the investigators hypothesize that a combined approach targeting different underlying mechanisms may provide a complementary and more effective protective effect than any single intervention alone. The PANENCA trial therefore evaluates whether the combined use of hydrocortisone, octreotide, and the ligamentum teres patch can reduce the rate of major postoperative complications after pancreatoduodenectomy.

Patients participating in the study are randomly assigned to receive either the combination treatment in addition to standard perioperative care or standard perioperative care alone. The study medications are administered only during the first postoperative days, and the surgical patch is applied during the operation itself. No additional tests, monitoring procedures, or hospital visits are required beyond routine clinical care.

This international, multicenter randomized trial includes patients at high risk for POPF who are undergoing pancreatoduodenectomy. The primary objective is to determine whether the combination treatment reduces the incidence of major postoperative complications. If proven effective, this bundle approach may be implemented more consistently across participating countries and incorporated into international clinical guidelines for pancreatic surgery.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Elective pancreatoduodenectomy for any indication (both minimally invasive and open)

Pancreatic duct diameter ≤ 3mm on preoperative CT or MRI*

18 years of age or older

Signature of informed consent

Disqualifiers

Age < 18 years

Pregnancy or current breastfeeding

Known allergy or hypersensitivity to hydrocortisone or octreotide

Systemic fungal infection

Trial design

Design model

Parallel

Treatments tested in this trial

  • HOP bundle

    Combination product

    Patients in the intervention group will receive the HOP bundle approach: * Hydrocortisone intravenous: 100mg hydrocortisone as sodium succinate i.v. starting during the induction of general anesthesia, administered every 8 hours until 2 days perioperative (last dose evening postoperative day 2) (total 9 dosages). * Octreotide subcutaneous: 0,1 mg every 8 hours during maximum 7 days, starting during the induction of general anesthesia, administered minimal 1 hour before surgery (to a maximum of 21 dosages or until earlier discharge). * Intraoperative coverage of the gastroduodenal artery stump using a teres ligament patch, separating it from the pancreato-enteric anastomosis.

Treatment groups

400 Participants
are divided into 2 treatment groups
Group A: Intervention arm (HOP bundle)Experimental treatment 1 intervention
Group B: Controle armNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Major complications

Rate of Major Complications, defined as a Clavien-Dindo score of ≥III and/or postoperative abdominal drain placement

Time frame
Until postoperative day 90

Secondary outcomes

1

Postoperative Pancreatic Fistula (POPF)

Rate of POPF grade B/C

Time frame
Until postoperative day 90

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Lead sponsor

Erasmus Medical Center

Collaborator

UMC Utrecht

Collaborator

Medisch Spectrum Twente

Collaborator

Jeroen Bosch Ziekenhuis

Collaborator

Maastricht University Medical Center

Collaborator

Radboud University Medical Center

Collaborator

Isala

Collaborator

Catharina Ziekenhuis Eindhoven

Collaborator

Helsinki University Central Hospital

Collaborator

Oslo University Hospital

Collaborator

Karolinska University Hospital

Collaborator

Sahlgrenska University Hospital

Collaborator

University Hospital, Linkoeping

Collaborator

Lund University Hospital

Collaborator

Azienda Ospedaliera Universitaria Integrata Verona

Collaborator

Azienda Ospedaliera di Padova

Collaborator

San Raffaele University Hospital, Italy

Collaborator

Leiden University Medical Center

Collaborator

University Medical Center Groningen

Collaborator

Clinical Cancer Hospital, Kyiv

Collaborator

Rigshospitalet, Denmark

Collaborator

University Hospital, Antwerp

Collaborator